Back to Search
Start Over
Dolutegravir Resistance in Malawi's National HIV Treatment Program.
- Source :
- Open Forum Infectious Diseases; May2022, Vol. 9 Issue 5, p1-5, 5p
- Publication Year :
- 2022
-
Abstract
- Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity. [ABSTRACT FROM AUTHOR]
- Subjects :
- DOLUTEGRAVIR
TREATMENT programs
ANTI-HIV agents
HIV
ANTIRETROVIRAL agents
Subjects
Details
- Language :
- English
- ISSN :
- 23288957
- Volume :
- 9
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Open Forum Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 156842705
- Full Text :
- https://doi.org/10.1093/ofid/ofac148